Buzzing Politics
  • News
  • Privacy Policy
  • Terms of Use
  • Disclaimer
Select Page

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

by Vandana Singh | Jun 15, 2026 | General

AstraZeneca Plc (NYSE:AZN) received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer therapy Truqap gaining approval for a subset of prostate cancer patients and its kidney disease treatment Ultomiris receiving Priority...

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

by Vandana Singh | Jun 15, 2026 | General

Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with...

Here’s How Much $100 Invested In Seagate Technology Hldgs 5 Years Ago Would Be Worth Today

by Benzinga Insights | Jun 15, 2026 | General

Seagate Technology Hldgs (NASDAQ:STX) has outperformed the market over the past 5 years by 50.85% on an annualized basis producing an average annual return of 63.62%. Currently, Seagate Technology Hldgs has a market capitalization of $226.32 billion. Buying $100 In...

TeraWulf Stock Is On The Rise: What’s Going On Today?

by Evette Mitkov | Jun 15, 2026 | General

TeraWulf Inc (NASDAQ:WULF) shares are flying on Monday. BofA Securities initiated coverage on the stock with a Buy rating and a $34 price objective. Here’s what you should know. TeraWulf stock is at critical resistance. What’s behind WULF new highs? BofA Initiates...

Stock Market Today: Nasdaq 100 Rallies, Oil Sinks 5% As U.S.-Iran Deal Reopens Hormuz

by Piero Cingari | Jun 15, 2026 | General

U.S. stocks rallied sharply on Monday after the United States and Iran signed a peace agreement that ends their war and reopens the Strait of Hormuz, sending crude oil tumbling roughly 5% to two-month lows and Treasury yields to one-month lows. The collapse in energy...

Elicio Therapeutics Pancreatic Cancer Study Disappoints

by Vandana Singh | Jun 15, 2026 | General

Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment....
« Older Entries
Next Entries »

Recent Posts

  • Stock Market: Will S&P 500 Open Up or Down Today?
  • GM CEO Mary Barra Says China’s Price War Isn’t ‘Sustainable,’ Backs Company’s Autonomous Driving Efforts Amid Nearly $11 Billion in EV Charges
  • Zohran Mamdani Admits NYC Can’t Arrest Benjamin Netanyahu, Citing Lack of ‘Legal Authority’— Urges Trump Administration to ‘Execute’ ICC Warrant
  • Nuvve Holding Stock Surges Nearly 24% After Hours: Why is it Moving?
  • Trump’s $10 Billion Media Lawsuit Turns Toward His Own Business Empire as Judge Allows BBC to Examine Finances of More Than 400 Companies

Recent Comments

    Archives

    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019

    Categories

    • Breaking
    • Business
    • Daily
    • General
    • Markets
    • News
    • Reports
    • Technology

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • News
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    Copyright 2019 Karmaholic Media LLC. All Rights Reserved.